Pradžia › Ūmi bifeninė leukemija › Texas
Ūmi bifeninė leukemija klinikiniai tyrimai Texas
13 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Texas.
Miestai Texas
- Houston11 tyrimai
- Dallas6 tyrimai
- Fort Worth5 tyrimai
- Corpus Christi3 tyrimai
- Austin3 tyrimai
- El Paso3 tyrimai
- San Antonio3 tyrimai
Oficialus tyrimo tekstas (anglų kalba)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius nuo 12 iki 78 · Visoms lytims · Atnaujinta 2026-09-29 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ir dar 7
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ir dar 12
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ir dar 10
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06177067Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 15 iki 80 · Visoms lytims · Atnaujinta 2026-07-30 · NCT02727803A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-06-22 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-12 · NCT04047641Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-05-20 · NCT02115295The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.